Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride (KCl) provides potassium ions, essential for maintenance of intracellular tonicity, nerve impulse transmission, muscle contraction, and enzymatic reactions. Dextrose 5% provides glucose for energy, and sodium chloride 0.45% provides sodium and chloride ions for electrolyte balance and volume expansion.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
40 mEq potassium chloride intravenously at a rate not exceeding 10 mEq/hour; typically infused over 4-6 hours. Maximum 24-hour dose: 200 mEq.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Terminal elimination half-life is approximately 3-5 minutes for rapid redistribution phase; effective half-life for total body potassium is 30-40 hours due to large intracellular pool. Clinical context: immediately after IV infusion, plasma potassium declines rapidly due to cellular uptake, but total elimination depends on renal function.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal: >90% excreted unchanged by kidneys. Fecal: <10% via secretion into feces.
Category C
Category A/B
Electrolyte
Electrolyte